Drug intelligence / Profile preview

CRB2107

Development stage: Preclinical
Lead developer: China Resources Angde Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

CRB2107 (also known as CRB-2107) is a preclinical-stage antibody-drug conjugate (ADC) being developed by China Resources Biopharmaceutical (China Resources Angde Biopharmaceutical) for the treatment of oncology indications. As of 2026, the specific target antigen, linker chemistry, and cytotoxic payload of CRB2107 remain undisclosed by the developer. The therapeutic candidate is designed to selectively deliver a cytotoxic agent to tumor cells, minimizing systemic toxicity and enhancing therapeutic efficacy in cancer patients.

Beyond the preview

Go deeper on CRB2107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRB2107.

Explore the full profile